KR102732030B1 - 아리피프라졸 주사가능한 제제의 투여 방법 - Google Patents

아리피프라졸 주사가능한 제제의 투여 방법 Download PDF

Info

Publication number
KR102732030B1
KR102732030B1 KR1020227037401A KR20227037401A KR102732030B1 KR 102732030 B1 KR102732030 B1 KR 102732030B1 KR 1020227037401 A KR1020227037401 A KR 1020227037401A KR 20227037401 A KR20227037401 A KR 20227037401A KR 102732030 B1 KR102732030 B1 KR 102732030B1
Authority
KR
South Korea
Prior art keywords
aripiprazole
injectable
salt
injectable formulation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227037401A
Other languages
English (en)
Korean (ko)
Other versions
KR20220161403A (ko
Inventor
매튜 하린
샤오펑 왕
옌린 왕
아라쉬 라오피니아
Original Assignee
오츠카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102732030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오츠카 세이야쿠 가부시키가이샤 filed Critical 오츠카 세이야쿠 가부시키가이샤
Priority to KR1020247038040A priority Critical patent/KR20240165486A/ko
Publication of KR20220161403A publication Critical patent/KR20220161403A/ko
Application granted granted Critical
Publication of KR102732030B1 publication Critical patent/KR102732030B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
KR1020227037401A 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법 Active KR102732030B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247038040A KR20240165486A (ko) 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247038040A Division KR20240165486A (ko) 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법

Publications (2)

Publication Number Publication Date
KR20220161403A KR20220161403A (ko) 2022-12-06
KR102732030B1 true KR102732030B1 (ko) 2024-11-20

Family

ID=75581573

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227037401A Active KR102732030B1 (ko) 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법
KR1020227037400A Pending KR20220161402A (ko) 2020-04-01 2021-04-01 아리피프라졸 치료의 용량 개시 방법
KR1020247038040A Pending KR20240165486A (ko) 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227037400A Pending KR20220161402A (ko) 2020-04-01 2021-04-01 아리피프라졸 치료의 용량 개시 방법
KR1020247038040A Pending KR20240165486A (ko) 2020-04-01 2021-04-01 아리피프라졸 주사가능한 제제의 투여 방법

Country Status (16)

Country Link
US (5) US20220160621A1 (https=)
EP (3) EP4125903B1 (https=)
JP (4) JP7584535B2 (https=)
KR (3) KR102732030B1 (https=)
CN (3) CN115397420A (https=)
AU (2) AU2021245713A1 (https=)
BR (2) BR112022018647A2 (https=)
CA (3) CA3136727A1 (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012353A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TWI865760B (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法
US20250387321A1 (en) 2023-03-17 2025-12-25 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
AU2024263986A1 (en) * 2023-04-26 2025-10-09 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
MX2009014115A (es) 2007-06-25 2010-04-21 Otsuka Pharma Co Ltd Microesferas que tienen estructura de nucleo/corteza.
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
JP2020520380A (ja) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CNS Drugs, 31(7), 617-624, 2017,
Expert Review of Clinical Pharmacology, 9(1), 169-186, 2015.

Also Published As

Publication number Publication date
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
EP3941470A1 (en) 2022-01-26
CN119792290A (zh) 2025-04-11
TW202200141A (zh) 2022-01-01
EP4467194A3 (en) 2025-01-08
US20240374506A1 (en) 2024-11-14
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
JP7733000B2 (ja) 2025-09-02
MX2022012353A (es) 2022-10-31
JP2023520004A (ja) 2023-05-15
AU2021248212A1 (en) 2022-12-01
KR20240165486A (ko) 2024-11-22
WO2021201239A1 (en) 2021-10-07
KR20220161402A (ko) 2022-12-06
JP7584535B2 (ja) 2024-11-15
US20260034053A1 (en) 2026-02-05
AU2021245713A1 (en) 2022-12-01
MX2022012354A (es) 2022-10-31
US20230129919A1 (en) 2023-04-27
US20220160621A1 (en) 2022-05-26
CN115379842A (zh) 2022-11-22
BR112022018647A2 (pt) 2022-11-08
HUE069157T2 (hu) 2025-02-28
CA3136727A1 (en) 2021-10-07
JP2025020306A (ja) 2025-02-12
CA3163321A1 (en) 2021-10-07
BR112022018721A2 (pt) 2022-11-01
EP4125903B1 (en) 2024-10-09
EP4125903A1 (en) 2023-02-08
EP4467194A2 (en) 2024-11-27
TWI865760B (zh) 2024-12-11
TW202523329A (zh) 2025-06-16
WO2021201238A1 (en) 2021-10-07
EP4125903C0 (en) 2024-10-09
US20230225962A1 (en) 2023-07-20
CN115397420A (zh) 2022-11-25
CA3163321C (en) 2023-12-19
JP2023519425A (ja) 2023-05-10
JP2025176037A (ja) 2025-12-03
PL4125903T3 (pl) 2025-02-03
ES2995466T3 (en) 2025-02-10
TWI906279B (zh) 2025-12-01
CA3212191A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
KR102732030B1 (ko) 아리피프라졸 주사가능한 제제의 투여 방법
JP6231385B2 (ja) 医薬組成物
KR102794804B1 (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
US10092523B2 (en) Long acting pharmaceutical compositions
JP2017132791A (ja) 組み合わせ組成物
US12329740B2 (en) Rescue treatment of post operative nausea and vomiting
JP5872551B2 (ja) パラセタモールを含む医薬組成物およびその製造法
CN110974828B (zh) 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物
US20260115131A1 (en) Methods of administering an aripiprazole injectable preparation
JP2006083190A (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
KR20100124860A (ko) 독소필린을 포함하는 변형 방출 조성물
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
CN107921023A (zh) 用于治疗偏头痛的包含舒马曲坦的药物组合物
KR20240134898A (ko) 백신 제제
HK40063844B (zh) 一种药物组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601